Search Results - "HAVRDOVA, Eva"

The potential of serum neurofilament as biomarker for multiple sclerosis by Bittner, Stefan, Oh, Jiwon, Havrdová, Eva Kubala, Tintoré, Mar, Zipp, Frauke

“…Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients…”
Get full text

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis by Fox, Robert J, Miller, David H, Phillips, J. Theodore, Hutchinson, Michael, Havrdova, Eva, Kita, Mariko, Yang, Minhua, Raghupathi, Kartik, Novas, Mark, Sweetser, Marianne T, Viglietta, Vissia, Dawson, Katherine T

“…In this trial involving patients with relapsing–remitting multiple sclerosis, BG-12 (dimethyl fumarate) reduced the annualized relapse rate and number of MRI…”
Get full text

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study by He, Anna, Merkel, Bernd, Brown, James William L, Zhovits Ryerson, Lana, Kister, Ilya, Malpas, Charles B, Sharmin, Sifat, Horakova, Dana, Kubala Havrdova, Eva, Spelman, Tim, Izquierdo, Guillermo, Eichau, Sara, Trojano, Maria, Lugaresi, Alessandra, Hupperts, Raymond, Sola, Patrizia, Ferraro, Diana, Lycke, Jan, Grand'Maison, Francois, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Larochelle, Catherine, Svenningsson, Anders, Petersen, Thor, Grammond, Pierre, Granella, Franco, Van Pesch, Vincent, Bergamaschi, Roberto, McGuigan, Christopher, Coles, Alasdair, Hillert, Jan, Piehl, Fredrik, Butzkueven, Helmut, Kalincik, Tomas

“…High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised…”
Get full text

Pregnancy‐induced brain magnetic resonance imaging changes in women with multiple sclerosis by Uher, Tomas, Kubala Havrdova, Eva, Vodehnalova, Karolina, Krasensky, Jan, Capek, Vaclav, Vaneckova, Manuela, Horakova, Dana

“…Background and purpose The effect of pregnancy on brain changes and radiological disease activity in women with multiple sclerosis (MS) is not well understood…”
Get full text

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, Xavier, Gold, Ralf, Thompson, Alan J, Otero-Romero, Susana, Amato, Maria Pia, Chandraratna, Dhia, Clanet, Michel, Comi, Giancarlo, Derfuss, Tobias, Fazekas, Franz, Hartung, Hans Peter, Havrdova, Eva, Hemmer, Bernhard, Kappos, Ludwig, Liblau, Roland, Lubetzki, Catherine, Marcus, Elena, Miller, David H, Olsson, Tomas, Pilling, Steve, Selmaj, Krysztof, Siva, Aksel, Sorensen, Per Soelberg, Sormani, Maria Pia, Thalheim, Christoph, Wiendl, Heinz, Zipp, Frauke

“…Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling…”
Get full text

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use by Havrdova, Eva, Horakova, Dana, Kovarova, Ivana

“…Alemtuzumab is a humanized monoclonal antibody therapy that has recently been approved in over 30 countries for patients with active relapsing-remitting…”
Get full text

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis by Kalincik, Tomas, Kubala Havrdova, Eva, Horakova, Dana, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Ozakbas, Serkan, Kappos, Ludwig, Kuhle, Jens, Terzi, Murat, Lechner-Scott, Jeannette, Boz, Cavit, Grand'Maison, Francois, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Trojano, Maria, Bergamaschi, Roberto, Pucci, Eugenio, Turkoglu, Recai, McCombe, Pamela A, Pesch, Vincent Van, Van Wijmeersch, Bart, Solaro, Claudio, Ramo-Tello, Cristina, Slee, Mark, Alroughani, Raed, Yamout, Bassem, Shaygannejad, Vahid, Spitaleri, Daniele, Sánchez-Menoyo, José Luis, Ampapa, Radek, Hodgkinson, Suzanne, Karabudak, Rana, Butler, Ernest, Vucic, Steve, Jokubaitis, Vilija, Spelman, Tim, Butzkueven, Helmut

“…ObjectiveOral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and…”
Get full text

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis by Kappos, Ludwig, Wiendl, Heinz, Selmaj, Krzysztof, Arnold, Douglas L, Havrdova, Eva, Boyko, Alexey, Kaufman, Michael, Rose, John, Greenberg, Steven, Sweetser, Marianne, Riester, Katherine, O’Neill, Gilmore, Elkins, Jacob

“…In this trial, daclizumab high-yield process (a monoclonal antibody that binds to CD25 and modulates interleukin-2 signaling) was more effective than…”
Get full text

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria by Polman, Chris H., Reingold, Stephen C., Banwell, Brenda, Clanet, Michel, Cohen, Jeffrey A., Filippi, Massimo, Fujihara, Kazuo, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Lublin, Fred D., Montalban, Xavier, O'Connor, Paul, Sandberg-Wollheim, Magnhild, Thompson, Alan J., Waubant, Emmanuelle, Weinshenker, Brian, Wolinsky, Jerry S.

“…New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of…”
Get full text

Freedom from disease activity in multiple sclerosis by Havrdova, Eva, Galetta, Steven, Stefoski, Dusan, Comi, Giancarlo

“…Multiple sclerosis (MS) shares many pathologic features with other immune-mediated inflammatory diseases, such as rheumatoid arthritis, Crohn disease, and…”
Get full text

Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis by Kalincik, Tomas, Sharmin, Sifat, Roos, Izanne, Massey, Jennifer, Sutton, Ian, Withers, Barbara, Freedman, Mark S, Atkins, Harold, Krasulova, Eva, Kubala Havrdova, Eva, Trneny, Marek, Kozak, Tomas, Burman, Joachim, Macdonell, Richard, Torkildsen, Øivind, Bø, Lars, Lehmann, Anne Kristine, Sharrack, Basil, Snowden, John

“…BackgroundNatalizumab was not shown to modify disability in progressive multiple sclerosis (MS). This matched observational study compared the effectiveness of…”
Get full text

Risk of secondary progressive multiple sclerosis: A longitudinal study by Fambiatos, Adam, Jokubaitis, Vilija, Horakova, Dana, Kubala Havrdova, Eva, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Lugaresi, Alessandra, Izquierdo, Guillermo, Grand’Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Terzi, Murat, Hupperts, Raymond, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Bergamaschi, Roberto, Van Pesch, Vincent, Ozakbas, Serkan, Granella, Franco, Turkoglu, Recai, Iuliano, Gerardo, Spitaleri, Daniele, McCombe, Pamela, Solaro, Claudio, Slee, Mark, Ampapa, Radek, Soysal, Aysun, Petersen, Thor, Sanchez-Menoyo, Jose Luis, Verheul, Freek, Prevost, Julie, Sidhom, Youssef, Van Wijmeersch, Bart, Vucic, Steve, Cristiano, Edgardo, Saladino, Maria Laura, Deri, Norma, Barnett, Michael, Olascoaga, Javier, Moore, Fraser, Skibina, Olga, Gray, Orla, Fragoso, Yara, Yamout, Bassem, Shaw, Cameron, Singhal, Bhim, Shuey, Neil, Hodgkinson, Suzanne, Altintas, Ayse, Al-Harbi, Talal, Csepany, Tunde, Taylor, Bruce, Hughes, Jordana, Jun, Jae-Kwan, van der Walt, Anneke, Spelman, Tim, Butzkueven, Helmut, Kalincik, Tomas

“…Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of…”
Get full text

Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry by Signori, Alessio, Ponzano, Marta, Kalincik, Tomas, Ozakbas, Serkan, Horakova, Dana, Kubala Havrdova, Eva, Alroughani, Raed, Patti, Francesco, Kuhle, Jens, Izquierdo, Guillermo, Eichau, Sara, Yamout, Bassem, Khoury, Samia Joseph, Karabudak, Rana, Grammond, Pierre, Duquette, Pierre, Roos, Izanne, Butzkueven, Helmut, van der Walt, Anneke, Sormani, Maria Pia

“…BackgroundTo mimic as closely as possible a randomised controlled trial (RCT) and calibrate the real-world evidence (RWE) studies against a known treatment…”
Get full text

Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis by Uher, Tomas, McComb, Mason, Galkin, Shery, Srpova, Barbora, Oechtering, Johanna, Barro, Christian, Tyblova, Michaela, Bergsland, Niels, Krasensky, Jan, Dwyer, Michael, Havrdova, Eva Kubala, Posova, Helena, Vaneckova, Manuela, Zivadinov, Robert, Horakova, Dana, Kuhle, Jens, Ramanathan, Murali

“…Background: Increased blood brain barrier (BBB) permeability, CNS inflammation and neuroaxonal damage are pathological hallmarks in early multiple sclerosis…”
Get full text

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials by Montalban, Xavier, Vermersch, Patrick, Arnold, Douglas L, Bar-Or, Amit, Cree, Bruce A C, Cross, Anne H, Kubala Havrdova, Eva, Kappos, Ludwig, Stuve, Olaf, Wiendl, Heinz, Wolinsky, Jerry S, Dahlke, Frank, Le Bolay, Claire, Shen Loo, Li, Gopalakrishnan, Sathej, Hyvert, Yann, Javor, Andrija, Guehring, Hans, Tenenbaum, Nadia, Tomic, Davorka

“…Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here,…”
Get full text

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 by Foong, Yi Chao, Merlo, Daniel, Gresle, Melissa, Buzzard, Katherine, Zhong, Michael, Yeh, Wei Zhen, Jokubaitis, Vilija, Monif, Mastura, Skibina, Olga, Ozakbas, Serkan, Patti, Francesco, Grammond, Pierre, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Kubala Havrdova, Eva, Weinstock-Guttman, Bianca, Lechner Scott, Jeanette, Boz, Cavit, Sa, Maria Jose, Butzkueven, Helmut, van der Walt, Anneke, Zhu, Chao, Skibina, Olga, Ozakbas, Serkan, Patti, Francesco, Grammond, Pierre, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Havrdova, Eva Kubala, Weinstock-Guttman, Bianca, Lechner-Scott, Jeannette, Boz, Cavit, Sa, Maria Jose, Butzkueven, Helmut, Walt, Anneke vander

“…BackgroundOngoing controversy exists regarding optimal management of disease modifying therapy (DMT) in older people with multiple sclerosis (pwMS). There is…”
Get full text

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial by Gold, Ralf, Prof, Giovannoni, Gavin, Prof, Selmaj, Krzysztof, Prof, Havrdova, Eva, Prof, Montalban, Xavier, Prof, Radue, Ernst-Wilhelm, Prof, Stefoski, Dusan, MD, Robinson, Randy, PhD, Riester, Katherine, MPH, Rana, Jitesh, MD, Elkins, Jacob, MD, O'Neill, Gilmore, MRCPI

“…Summary Background Daclizumab, a humanised monoclonal antibody, modulates interleukin-2 signalling by blocking the α subunit (CD25) of the interleukin-2…”
Get full text

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study by Havrdova, Eva, MD, Galetta, Steven, MD, Hutchinson, Michael, MD, Stefoski, Dusan, MD, Bates, David, MD, Polman, Chris H, MD, O'Connor, Paul W, MD, Giovannoni, Gavin, PhD, Phillips, J Theodore, MD, Lublin, Fred D, MD, Pace, Amy, ScD, Kim, Richard, MD, Hyde, Robert, PhD

“…Summary Background The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting…”
Get full text

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial by Coles, Alasdair J, Dr, Twyman, Cary L, MD, Arnold, Douglas L, Prof, Cohen, Jeffrey A, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Miller, Tamara, MD, Fisher, Elizabeth, PhD, Sandbrink, Rupert, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Oyuela, Pedro, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

“…Summary Background The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple…”
Get full text

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial by Cohen, Jeffrey A, Prof, Coles, Alasdair J, PhD, Arnold, Douglas L, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Fisher, Elizabeth, PhD, Brinar, Vesna V, MD, Giovannoni, Gavin, Prof, Stojanovic, Miroslav, MD, Ertik, Bella I, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

“…Summary Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with…”
Get full text